SPA
VIR icon

Sherbrooke Park Advisers’s Vir Biotechnology VIR Stock Holding History

Sherbrooke Park Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,719
Closed -$148K – 1184
2024
Q3 		$148K Buy
+19,719
New +$171K 0.03% 798
2023
Q4 		– Sell
-10,531
Closed -$98.7K – 696
2023
Q3 		$98.7K Buy
+10,531
New +$150K 0.03% 453

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Sherbrooke Park Advisers's VIR Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 19,719 shares — an estimated $148K sold.

Sherbrooke Park Advisers first reported a position in VIR in Q3 2023 and held it in 2 quarters. The position peaked at $148K in Q3 2024. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 19,719 Vir Biotechnology shares in Q4 2024, an estimated $148K.
  • Sherbrooke Park Advisers first reported a position in Vir Biotechnology in Q3 2023 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Vir Biotechnology position peaked at $148K in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.